KR101042660B1 - 안정한 액체 인터페론 제제 - Google Patents

안정한 액체 인터페론 제제 Download PDF

Info

Publication number
KR101042660B1
KR101042660B1 KR1020077010020A KR20077010020A KR101042660B1 KR 101042660 B1 KR101042660 B1 KR 101042660B1 KR 1020077010020 A KR1020077010020 A KR 1020077010020A KR 20077010020 A KR20077010020 A KR 20077010020A KR 101042660 B1 KR101042660 B1 KR 101042660B1
Authority
KR
South Korea
Prior art keywords
interferon
beta
package kit
liquid composition
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077010020A
Other languages
English (en)
Korean (ko)
Other versions
KR20070052363A (ko
Inventor
마리 디. 디비아시
마크 스테이플스
웬리 충
에릭 샤린
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101042660(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20070052363A publication Critical patent/KR20070052363A/ko
Application granted granted Critical
Publication of KR101042660B1 publication Critical patent/KR101042660B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020077010020A 1996-12-24 1997-12-23 안정한 액체 인터페론 제제 Expired - Lifetime KR101042660B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
US60/034,353 1996-12-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1019997005701A Division KR20000069664A (ko) 1996-12-24 1997-12-23 안정한 액체 인터페론 제제

Publications (2)

Publication Number Publication Date
KR20070052363A KR20070052363A (ko) 2007-05-21
KR101042660B1 true KR101042660B1 (ko) 2011-06-20

Family

ID=21875893

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077010020A Expired - Lifetime KR101042660B1 (ko) 1996-12-24 1997-12-23 안정한 액체 인터페론 제제
KR1019997005701A Ceased KR20000069664A (ko) 1996-12-24 1997-12-23 안정한 액체 인터페론 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019997005701A Ceased KR20000069664A (ko) 1996-12-24 1997-12-23 안정한 액체 인터페론 제제

Country Status (27)

Country Link
EP (1) EP0948358B2 (https=)
JP (5) JP4878664B2 (https=)
KR (2) KR101042660B1 (https=)
CN (2) CN1222315C (https=)
AT (1) ATE270899T1 (https=)
AU (1) AU738362B2 (https=)
BG (2) BG65171B1 (https=)
BR (1) BR9714434A (https=)
CA (1) CA2275890C (https=)
CZ (1) CZ300636B6 (https=)
DE (1) DE69729880T3 (https=)
DK (1) DK0948358T4 (https=)
EA (1) EA002754B1 (https=)
EE (2) EE04223B1 (https=)
ES (1) ES2224290T5 (https=)
HU (1) HU224222B1 (https=)
IL (1) IL130524A (https=)
IS (1) IS2070B (https=)
MX (1) MX337876B (https=)
NO (1) NO327844B1 (https=)
NZ (2) NZ336548A (https=)
PL (1) PL193447B1 (https=)
PT (1) PT948358E (https=)
SI (1) SI0948358T2 (https=)
SK (1) SK284989B6 (https=)
TR (1) TR199901968T2 (https=)
WO (1) WO1998028007A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EP1426058A3 (de) 1997-09-23 2004-07-28 Dr. Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
CN100448482C (zh) * 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
KR101149454B1 (ko) * 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2318575T3 (es) 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
AU2006204937B2 (en) * 2005-01-12 2011-02-10 Biogen Ma Inc. Method for delivering Interferon-beta
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
DE602006020568D1 (de) 2005-07-02 2011-04-21 Arecor Ltd Stabile wässrige systeme mit proteinen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2638977T3 (es) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
JP5563475B2 (ja) 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN102066401A (zh) 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2649993B1 (en) * 2010-12-09 2017-04-05 Maruishi Pharmaceutical Co., Ltd. Stabilizer of acetaminophen
EP2686002B1 (en) 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013159057A1 (en) * 2012-04-19 2013-10-24 C. R. Bard, Inc. Infusates with enhanced ph stability under ethylene oxide sterilization
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
JP2023524248A (ja) * 2020-04-29 2023-06-09 アビオン インク． 二重突然変異を有するヒトインターフェロン－ベータ変異体及びヒトインターフェロン－ベータ変異体の安全性を向上させる方法
WO2022207655A1 (en) * 2021-03-30 2022-10-06 Schott Schweiz Ag System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
WO2023129502A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163111A2 (en) * 1984-04-28 1985-12-04 Kyowa Hakko Kogyo Co., Ltd. Method for solubilization of interferon
WO1995031213A1 (en) * 1994-05-16 1995-11-23 Applied Research Systems Ars Holding N.V. IFN-β LIQUID FORMULATIONS
EP0736303A2 (en) * 1995-04-06 1996-10-09 F. Hoffmann-La Roche Ag Interferon solution

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (https=) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
WO1995027499A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163111A2 (en) * 1984-04-28 1985-12-04 Kyowa Hakko Kogyo Co., Ltd. Method for solubilization of interferon
WO1995031213A1 (en) * 1994-05-16 1995-11-23 Applied Research Systems Ars Holding N.V. IFN-β LIQUID FORMULATIONS
EP0736303A2 (en) * 1995-04-06 1996-10-09 F. Hoffmann-La Roche Ag Interferon solution

Also Published As

Publication number Publication date
JP5851695B2 (ja) 2016-02-03
PL334365A1 (en) 2000-02-28
HU224222B1 (hu) 2005-06-28
EP0948358B2 (en) 2011-11-23
MX337876B (es) 2016-03-22
JP2012006979A (ja) 2012-01-12
NZ336548A (en) 2001-09-28
DK0948358T3 (da) 2004-11-08
PL193447B1 (pl) 2007-02-28
EE04266B1 (et) 2004-04-15
BG65418B1 (bg) 2008-07-31
KR20070052363A (ko) 2007-05-21
HUP0000829A2 (en) 2000-07-28
SK284989B6 (sk) 2006-04-06
IS5087A (is) 1999-06-21
IL130524A (en) 2005-08-31
SI0948358T1 (en) 2005-04-30
HK1092048A1 (zh) 2007-02-02
EP0948358A1 (en) 1999-10-13
EA002754B1 (ru) 2002-08-29
HUP0000829A3 (en) 2002-01-28
NZ512792A (en) 2002-11-26
BR9714434A (pt) 2000-05-02
CN1733296B (zh) 2010-05-26
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
CZ300636B6 (cs) 2009-07-08
DE69729880T2 (de) 2005-07-07
IL130524A0 (en) 2000-06-01
KR20000069664A (ko) 2000-11-25
CN1733296A (zh) 2006-02-15
BG65171B1 (bg) 2007-05-31
CA2275890A1 (en) 1998-07-02
AU738362B2 (en) 2001-09-13
EE200300127A (et) 2003-06-16
CN1245434A (zh) 2000-02-23
PT948358E (pt) 2004-10-29
JP2001519770A (ja) 2001-10-23
EE04223B1 (et) 2004-02-16
JP2011068694A (ja) 2011-04-07
NO327844B1 (no) 2009-10-05
EA199900597A1 (ru) 2000-02-28
HK1025040A1 (en) 2000-11-03
DK0948358T4 (da) 2012-03-19
NO993121L (no) 1999-08-24
SK85899A3 (en) 2000-01-18
JP2007204501A (ja) 2007-08-16
DE69729880D1 (de) 2004-08-19
ATE270899T1 (de) 2004-07-15
NO993121D0 (no) 1999-06-23
BG103594A (en) 2000-04-28
ES2224290T5 (es) 2012-03-12
DE69729880T3 (de) 2012-05-10
IS2070B (is) 2005-12-15
SI0948358T2 (sl) 2012-03-30
BG109523A (en) 2007-05-31
EP0948358B1 (en) 2004-07-14
JP4878664B2 (ja) 2012-02-15
AU5619198A (en) 1998-07-17
CN1222315C (zh) 2005-10-12
WO1998028007A1 (en) 1998-07-02
EE9900313A (et) 2000-04-17
TR199901968T2 (xx) 1999-12-21
CA2275890C (en) 2011-11-01
ES2224290T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
KR101042660B1 (ko) 안정한 액체 인터페론 제제
US9522174B2 (en) Stable liquid interferon beta formulations
JP4988562B2 (ja) 安定化したインターフェロン液体製剤
HK1025040B (en) Stable liquid interferon formulations
MXPA99005977A (en) Stable liquid interferon formulations
HK1092048B (en) Stable liquid interferon formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070502

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070531

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070821

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080714

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080714

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090916

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090615

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110415

Appeal identifier: 2009101008599

Request date: 20090916

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090916

Effective date: 20110415

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20110415

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090916

Decision date: 20110415

Appeal identifier: 2009101008599

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20110506

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20110420

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110613

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140528

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140528

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150527

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150527

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170531

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170531

Start annual number: 7

End annual number: 7

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20180623

Termination category: Expiration of duration